Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AtriCure, Inc. Director's Dealing 2020

Feb 24, 2020

31802_dirs_2020-02-24_68511a5a-b963-4a0e-af07-5ed6eab7c27f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AtriCure, Inc. (ATRC)
CIK: 0001323885
Period of Report: 2020-02-21

Reporting Person: Wade M. Andrew (CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-02-21 Common Stock M 15000 $6.27 Acquired 160120 Direct
2020-02-21 Common Stock S 15000 $39.45 Disposed 145120 Direct
2020-02-21 Common Stock M 15000 $6.73 Acquired 160120 Direct
2020-02-21 Common Stock S 15000 $39.46 Disposed 145120 Direct
2020-02-21 Common Stock M 15000 $6.73 Acquired 160120 Direct
2020-02-21 Common Stock S 15000 $39.45 Disposed 145120 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-02-21 Stock Option (Right to Buy) $6.27 M 15000 Disposed 2022-10-25 Common Stock (15000) Direct
2020-02-21 Stock Option (Right to Buy) $6.73 M 15000 Disposed 2022-12-27 Common Stock (15000) Direct
2020-02-21 Stock Option (Right to Buy) $6.73 M 15000 Disposed 2022-12-27 Common Stock (15000) Direct

Footnotes

F1: These shares were exercised pursuant to a 10b5-1 trading plan.

F2: These shares were sold pursuant to a 10b5-1 trading plan.

F3: This transaction was executed in multiple trades at prices ranging from $38.94 to $40.60 per share. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: These options were granted on October 25, 2012. The options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.

F5: These options were granted on December 27, 2012 and are exercisable as to 25% of the shares one year from the date of grant, and the remaining 75% thereafter vests and is exercisable in equal monthly installments on the same day of the month over the following three years.